News

From the College of Natural Sciences
Font size: +

Six College of Natural Sciences Faculty Bring In $6.4 Million for Groundbreaking Cancer Research

Six College of Natural Sciences Faculty Bring In $6.4 Million for Groundbreaking Cancer Research
Rising young researcher and new recruit one of esteemed group of faculty receiving a new round of grants from the Cancer Prevention Research Institute of Texas.
 

Upton JW-office-treatedJason Upton, a new assistant professor of molecular genetics and microbiology, received $2 million for his cancer research from CPRIT.AUSTIN, Texas — To support fundamental cancer research, six faculty in the College of Natural Sciences were awarded a total of $6.4 million of funding in November from the Cancer Prevention Research Institute of Texas (CPRIT), including new faculty recruit Jason Upton.

With a $2 million startup grant, Upton will continue his efforts to improve existing cancer therapies and develop new ones. He investigates how programmed cell death pathways are dysregulated in tumor cells.

One of CPRIT’s goals is to attract top cancer scientists to Texas. Upton, who will start his position as an assistant professor of molecular genetics and microbiology in January 2012, joins the faculty from Emory University in Atlanta.

Recipients include:

George Georgiou, professor of chemical and biomedical engineering and molecular genetics and microbiology. Georgiou received $200,000 to develop a human version of the therapeutic enzyme asparaginase that displays fewer adverse side effects than the bacterial enzyme that is currently used in treating pediatric and adult leukemias and other cancers.

Vishy Iyer, associate professor of molecular genetics and microbiology. Iyer received $1.1 million to use next-generation sequencing technologies to identify and study the role of noncoding DNA variants in gene regulation as a means to diagnose and develop personalized therapies for a common brain cancer in collaboration with Matt Cowperthwaite, director of research at the NeuroTexas Institute at St. David's HealthCare.

Edward Marcotte, professor of chemistry and biochemistry. Marcotte received $200,000 to develop a large-scale, rapid method for diagnosing and characterizing cancers noninvasively using fluids such as saliva, blood and urine by identifying and quantifying individual peptides or proteins that point to the presence of cancer in the body.

Jonathan Sessler, professor of chemistry and biochemistry. Sessler received $1.3 million to further develop and study texaphyrin-platinum conjugates as a less toxic treatment option for many cancers, including lung and ovarian cancer.

Philip Tucker, professor of molecular genetics and microbiology. Tucker received $948,000 to further characterize how transcriptional deregulation leads to the development of diffuse large B-cell lymphoma, one of the most common and aggressive types of malignancy.

Steven Vokes, assistant professor of molecular, cell and developmental biology. Vokes received $660,000 to better understand how aberrancies in the cellular signaling pathway known as “Hedgehog” lead to basal cell carcinomas, the most common form of cancer in humans. The research will identify the genes directly activated by Hedgehog signaling and provide a framework for understanding how the activation occurs. The identification of these genes should enable the generation of more specific cancer therapies.

CPRIT is a state agency that was created when Texas voters overwhelmingly approved a 2007 constitutional amendment authorizing the state to issue $3 billion in bonds to fund groundbreaking cancer research and prevention programs and services in Texas. CPRIT’s goal is to expedite innovation and commercialization in the area of cancer research and to enhance access to evidence-based prevention programs and services throughout the state.

Dr. Fink's Little Black Box
Pair of Black Holes "Weigh In" at 10 Billion Suns;...

Comments 1

 
Guest - Heartha Whitlow on Thursday, 08 December 2011 04:28

I am so glad that Jonathan Sessler is working on ovarian cancer. It is being grossly neglected.
I have Stage 3 and have been doing chemo for 4 1/2 years.
good luck, Dr. Sessler.
Heartha Whitlow

I am so glad that Jonathan Sessler is working on ovarian cancer. It is being grossly neglected. I have Stage 3 and have been doing chemo for 4 1/2 years. good luck, Dr. Sessler. Heartha Whitlow
Already Registered? Login Here
Guest
Tuesday, 26 September 2017

Captcha Image